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Abstract
Background: Cellular-based therapies represent a platform technology within the rapidly expanding field of
regenerative medicine and are distinct from conventional therapeutics—offering a unique approach to managing
what were once considered untreatable diseases. Despite a significant increase in basic science activity within the
cell therapy arena, alongside a growing portfolio of cell therapy trials and promising investment, the translation of
cellular-based therapeutics from “bench to bedside” remains challenging, and the number of industry products
available for widespread clinical use remains comparatively low. This systematic review identifies unique intrinsic
and extrinsic barriers in the cell-based therapy domain.
Methods/design: Eight electronic databases will be searched, specifically Medline, EMBASE (OvidSP), BIOSIS & Web of
Science, Cochrane Library & HEED, EconLit (ProQuest), WHOLIS WHO Library Database, PAIS International (ProQuest),
and Scopus. Addition to this gray literature was searched by manually reviewing relevant work. All identified articles
will be subjected for review by two authors who will decide whether or not each article passes our inclusion/exclusion
criteria. Eligible papers will subsequently be reviewed, and key data extracted into a pre-designed data extraction
scorecard. An assessment of the perceived impact of broad commercial barriers to the adoption of cell-based therapies
will be conducted. These broad categories will include manufacturing, regulation and intellectual property,
reimbursement, clinical trials, clinical adoption, ethics, and business models. This will inform further discussion in the
review. There is no PROSPERO registration number.
Discussion: Through a systematic search and appraisal of available literature, this review will identify key challenges in
the commercialization pathway of cellular-based therapeutics and highlights significant barriers impeding successful
clinical adoption. This will aid in creating an adaptable, acceptable, and harmonized approach supported by apposite
regulatory frameworks and pertinent expertise throughout the respective stages of the adoption cycle to facilitate the
adoption of new products and technologies in the industry.
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Review background
As a key constituent of regenerative medicine, cell-
based therapies are an exciting platform technology
with the prospect of potentially curing what were
once considered untreatable diseases [1]. Defined by
the BSI (British Standards Institute) as “the thera-
peutic application of cells regardless of cell type or
clinical indication” [2], they present a scientifically,
commercially, and clinically important treatment mo-
dality. They are distinct from conventional pharma-
ceuticals, biologics, and medical devices through their
capacity to facilitate the de novo production of func-
tional tissue [2] and potential ability to remedy, rather
than ameliorate, a spectrum of medical and surgical
diseases. Consequently, this has made them attractive
to a number of stakeholders, including healthcare
practitioners, industry, and investors—all of whom are
driving a paradigm shift away from conventional dis-
ease management [3].
The cell therapy industry centers on the notion of
therapeutically utilizing cells across a multiplicity of
disease indications, spanning diverse fields such as
neurology, cardiology, and ophthalmology, and extend-
ing to both chronic and acute disease states [4, 5]. Des-
pite its relative infancy, it has successfully established
itself as a billion-dollar industry [3, 6], which is pro-
jected to grow—supported by an increasing number of
marketable products, fiscal investment, and strong
M&A (merger and acquisition) activity [7]. In 2014
alone, venture capital investment into the biotech sec-
tor surpassed $9 billion (USD) [8] and transformed an
industry historically plagued by overly exuberant invest-
ments and multibillion-dollar losses [9] into a stable
and sustainable market that appears attractive for both
future investment and long-term value.
Purpose
This systematic review will critically examine key chal-
lenges in the commercialization pathway of cellular-based
therapeutics and highlights significant barriers impeding
successful clinical adoption. This will help formulate an
adaptable and harmonized approach to commercialization
that is aligned with appropriate regulatory frameworks,
whilst providing evidence-based recommendations for the
adoption cycle. Ultimately, this will help expedite the
availability of efficacious medical treatments to patients
with high, unmet clinical needs.
Previous reviews and rationale
Although most cell therapies are currently in pre-launch
discovery phases (see Fig. 1), a number of products have
achieved success across EU (European Union), US
(United States), and global marketplaces. However, des-
pite a promising global demand and favorable invest-
ment, the translation of cellular-based therapeutics from
“bench to bedside” remains challenging. Difficulties per-
taining to healthcare translation are nothing new—the
2006 Cooksey Report [10] identified two major transla-
tional gaps in health research, namely translating basic
science and clinical research into ideas and products,
and subsequently introducing these into clinical practi-
ce—both of which are relatable to cell therapies. Trans-
lational difficulties, and in particular, the clinical
adoption of a therapeutic agent, encompass a complex
series of processes and relationships between heteroge-
neous stakeholder groups.
There are a number of review published that look to
assess barriers to the development of cell-based therap-
ies. An example is a study conducted by Dodson et al.
(2015), who retrospectively analyzed the development of
seven cell-based therapies [11]. They concluded that
Fig. 1 The current regenerative medicine landscape. Compiled using Thomson Reuters Cortellis™ competitive intelligence software. Gene therapy
candidates currently lead the Discovery phase, whilst most Launched drugs comprise tissue-engineered products (including skin substitutes). MSC:
mesenchymal stem cell, AAV: adeno-associated virus
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funding, regulation, lack of scientific understanding, re-
imbursement, and manufacturing are key areas dampen-
ing the development of such technology. To the best of
our knowledge, however, no systematic evaluation has been
conducted to assess the barriers to the commercialization
of cell-based therapies. This is a need addressed within this
study and is essential to remove bias that may exist when
evaluating isolated technologies. Qualitative studies have
been previously conducted will also lay the foundation for
our pilot data extraction sheet.
Methods/design
This systematic review will be reported following the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [12]. Because this
review will only use publically available information, an
ethics review board approval will not be required.
Eligibility criteria
English language manuscripts published within the last
5 years will be included in this review. Inclusion and ex-
clusion criteria to be used are listed in Table 1.
Search strategy and search term development
A review of the literature will be conducted to iden-
tify published studies from the following biblio-
graphic databases: Ovid MEDLINE, Ovid EMBASE,
Cochrane Library, EconLit, BIOSIS, WHOLIS, PAIS
International, and Scopus. Due to social science
work within the area, a manual review of relevant
journals will also be carried out.
The search strategy will be developed using key-
words and controlled vocabulary terms (e.g., National
Library of Medicine’s Medical Subject Headings).
Additional papers will be obtained through the use of
citation-tracking software, pursuing bibliographical
references of papers electronically identified in the
database searches and through further exploration of
gray literature (Tables 2 and 3).
Key data regarding electronic database and Thomson
Reuters Cortellis™ searches is provided below.
The above electronic databases were first accessed on
17 November 2015.
Key words and medical subheadings:
Subheadings: cell therapy; biomedical technology as-
sessment; cost benefit analysis; financial management;
economic aspect; commercial phenomena; biological ther-
apy; cell therapy; cost; healthcare cost; stem cell; regen-
erative medicine
Key words: commercialization; cell therapy; reimburse-
ment; barrier; regenerative medicine
Thomson Reuters Cortellis™ Competitive Intelligence
Software:
This software will be searched to identify cell therapy
products from 01/01/2010 to 01/05/2016 (access date:
01/05/2016). Identified products will be stratified by
phase, i.e., launched (in market) or in discovery phase.
Key search terms: cell therapy; gene therapy (limited to
AAV and lentivirus); mesenchymal stem cell
Study selection
Two independent reviewers will screen manuscript titles
and abstracts for relevance, and full text papers will be
obtained for further citations deemed potentially appro-
priate. Reviewer discrepancies will be discussed until
consensus is reached. Full text papers will then be
assessed for eligibility according to predefined inclusion
and exclusion criteria (as listed in Table 1).
Eligible papers will be subsequently reviewed and key
data extracted into a pre-designed data extraction score-
card. An overview of the methodology can be seen in
Fig. 2 below:
Synthesis
The data synthesis and extraction scorecard will be cate-
gorized into eight key domains, which are outlined
below:
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Published within the last 5 years
• English language publications
• Addressed regenerative medicines
o Autologous or allogeneic
• Identified potential challenges in
the commercialization or clinical
adoption process
• Exclusive focus on manufacturing
• Technical papers examining
isolation techniques, drug delivery
systems or bioprocessing practices
• Non-human or veterinary focus
• Conference abstracts
• Book chapters
• Competing interests—sponsored
by manufacturer
Table 2 Database search summary
Database Results
(n =)
Selected
(n =)
MEDLINE (OvidSP) 145 62
EMBASE (OvidSP) 1580 194
Cochrane Library & HEED 104 0
EconLit (ProQuest) 296 29
BIOSIS & Web of Science (Thomson Reuters) 159 37
WHOLIS, WHO Library Database 12 0
PAIS International, ProQuest 12 8
Scopus 1181 147
Gray literature/hand search – 31
Subtotal (n =) 3489
(3520 inc gray)
508
Duplicates 146
Total 362
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1. Manufacturing
2. Regulation and intellectual property
3. Reimbursement
4. Clinical Trials
5. Clinical Adoption
6. Ethics
7. Business models
8. Other
Such domains were identified as being key through brief
review of the literature in the area. Each domain will be
further subcategorized into important components, e.g.,
within the Manufacturing domain, subcategories will
include Scalability, Automation, and Supply Chain. The
tabulated scorecard serves to:
i. Facilitate the assignment of a perceived impact and/
or importance score
ii. Serve as a record of frequency for which a barrier/
domain was mentioned in a manuscript
The data synthesis and extraction scorecard will be
piloted on a sample of 23 manuscripts and completed by
two independent reviewers. The pilot sample will be ac-
quired from the 83 records identified by stratifying them
according to highest impact factor journal (n = 13) and
Table 3 MeSH terms
Concept 1 Concept 2 Concept 3 Concept 4 Concept 5
Subject
heading
Clinical adoption
MeSH: Technology
assessment, Biomedical,
Cost-Benefit Analysis
Cell-based therapeutics
MeSH: Cell- and Tissue-Based
Therapy, MeSH: biological
therapy, MeSH: Regenerative
Medicine
Conventional therapeutics MeSH:
Therapeutics, Drug Therapy,
Enzyme therapy, Molecular
Targeted Therapy,
Immunotherapy, Transplantation,
Monoclonal Antibodies, Vaccines,
biosimilars, small-molecule drugs
Emerging
technologies MeSH:
technology
assessment,
Biomedical, High-Cost
Technology
Barriers
Keywords Clinical adoption,
implementation,
technology assessment,
appraisal, tools,
methodology,
commercialization
Biologics, gene therapy,
regenerative medicines, cell-
and tissue-based therapy,
stem cells, tissue
engineering
Medicines, pharmacological
agents, organ transplant,
monoclonal, vaccine
Translational medical
research
Fig. 2 Systematic review methodological overview
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number of paper citations (n = 10). The scorecard will
subsequently be applied to all 83 identified records and
completed by two independent reviewers. The IRR
(inter-rater reliability) will be calculated following analysis.
The data synthesis and extraction scorecard will score
each paper on the perceived impact and importance of a
cited factor, as seen below in Table 4.
The excerpt above displays a linear scale ranging from
Essential to Negligible, which is accompanied by a
numerical value (see parenthesis). The scorecard will
also facilitate the documentation of additional informa-
tion, including publication details (e.g., year, journal,
country of publication), cell-based therapy characteris-
tics (e.g., therapeutic indication, autologous vs. allogen-
eic, cell type), generalizability (e.g., if nature of findings
are limited to a particular region by the regulatory sys-
tem described), and sources of funding and potential
conflicts of interest. An additional free text box will be
included for “other” challenges or barriers identified in
the reviewed manuscripts that did not fall into one of
the predetermined domains or subcategories.
A PRISMA-P file is included as Additional file 1.
There is no PROSPERO registration number.
Discussion
This systematic review will critically examine key chal-
lenges in the commercialization pathway of cellular-
based therapeutics and highlights significant barriers
impeding successful clinical adoption. This will help
formulate an adaptable and harmonized approach to
commercialization that is aligned with appropriate
regulatory frameworks, whilst providing evidence-based
recommendations for the adoption cycle. Ultimately,
this will help expedite the availability of efficacious
medical treatments to patients with high, unmet clinical
needs.
A number of limitations will be inherent to this study.
Notably, the assignment of an impact score is subjective
and open to reviewer interpretation. Publication bias is also
inherent to the academic literature and it is plausible that
more important or challenging commercialization barriers
are more widely discussed and, consequently, published.
Challenges are also experience-dependent. Cell therapy
developers may therefore have a greater degree of real-world
experience with the initial phases of commercialization, e.g.,
manufacturing or seeking regulatory approval with
demonstrable clinical trial data, in comparison to the lat-
ter phases, such as clinical adoption or reimbursement.
Due to the rapid evolution of the regenerative medi-
cine field, it was deemed appropriate to only include pa-
pers published in the last 5 years. It is however likely
that a number of studies published at the beginning of
this period are now outdated. It may also be possible
that a number of relevant studies published prior to this
time period contain valid arguments for ongoing
commercialization challenges and may have been
missed. The study was also limited to English language
publications, which may have resulted in research find-
ings, particularly from South East Asian nations with
novel regulatory mechanisms, being excluded. Such limi-
tations can be mitigated in future research that employs
more extensive inclusion criteria and regularly re-visits
key literature sources.
Additional file
Additional file 1: PRISMA-P (Preferred Reporting Items for Systematic
review and Meta-Analysis Protocols) 2015 checklist: recommended items
to address in a systematic review protocol*. (DOC 81 kb)
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